What is the projected market valuation of the Viral Disease Diagnosis Market by 2035?

The Viral Disease Diagnosis Market is projected to reach a valuation of 17.39 USD Billion by 2035. Read More

What was the market valuation of the Viral Disease Diagnosis Market in 2024?

In 2024, the market valuation of the Viral Disease Diagnosis Market was 9.37 USD Billion. Read More

What is the expected CAGR for the Viral Disease Diagnosis Market during the forecast period 2025 - 2035?

The expected CAGR for the Viral Disease Diagnosis Market during the forecast period 2025 - 2035 is 5.78%. Read More

Which companies are considered key players in the Viral Disease Diagnosis Market?

Key players in the Viral Disease Diagnosis Market include Abbott Laboratories, Roche Diagnostics, and Thermo Fisher Scientific, among others. Read More

What segment of the Viral Disease Diagnosis Market is projected to have the highest valuation by 2035?

By 2035, the segment for Nucleic Acid Amplification Tests (NAATs) is projected to reach a valuation of 5.25 USD Billion. Read More

How does the valuation of the HIV segment compare to that of the Hepatitis segment by 2035?

By 2035, the HIV segment is projected to reach 3.45 USD Billion, while the Hepatitis segment is expected to reach 2.8 USD Billion. Read More

What is the projected valuation for the Diagnostics application segment by 2035?

The Diagnostics application segment is projected to reach a valuation of 6.92 USD Billion by 2035. Read More

Which specimen type is expected to show significant growth in the Viral Disease Diagnosis Market?

The Swabs specimen type is expected to grow significantly, with a projected valuation of 2.8 USD Billion by 2035. Read More

What is the anticipated market size for the Laboratories end user segment by 2035?

The Laboratories end user segment is anticipated to reach a market size of 4.3 USD Billion by 2035. Read More

How does the projected growth of the Viral Disease Diagnosis Market reflect on public health initiatives?

The projected growth of the Viral Disease Diagnosis Market indicates a potential increase in public health initiatives, particularly in diagnostics and surveillance. Read More

Viral Disease Diagnosis Market

Viral disease diagnosis market Research Report By Disease Type (HIV, Hepatitis, Influenza, Respiratory Syncytial Virus (RSV), Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Herpes Simplex Virus (HSV)), By Specimen Type (Blood, Urine, Saliva, Swabs, Sputum, Stool), By Technology (Nucleic Acid Amplification Tests (NAATs), Immunoassays, Serology Tests, Molecular Diagnostics, Rapid Diagnostic Tests), By Application (Diagnostics, Surveillance, Treatment Monitoring, Prognosis), By End User (Hospitals, Clinics, Laboratories, Research Institutions, Public Health Agencies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.78%

2024 Market Size

$ 9.37 Billion

2035 Market Size

$ 17.39 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/26272-HCR | Pages: 100 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Disease Type (USD Billion)
  1. 4.1.1 HIV
  2. 4.1.2 Hepatitis
  3. 4.1.3 Influenza
  4. 4.1.4 Respiratory Syncytial Virus (RSV)
  5. 4.1.5 Cytomegalovirus (CMV)
  6. 4.1.6 Epstein-Barr Virus (EBV)
  7. 4.1.7 Herpes Simplex Virus (HSV)
2. 4.2 Healthcare, BY Specimen Type (USD Billion)
  1. 4.2.1 Blood
  2. 4.2.2 Urine
  3. 4.2.3 Saliva
  4. 4.2.4 Swabs
  5. 4.2.5 Sputum
  6. 4.2.6 Stool
3. 4.3 Healthcare, BY Technology (USD Billion)
  1. 4.3.1 Nucleic Acid Amplification Tests (NAATs)
  2. 4.3.2 Immunoassays
  3. 4.3.3 Serology Tests
  4. 4.3.4 Molecular Diagnostics
  5. 4.3.5 Rapid Diagnostic Tests
4. 4.4 Healthcare, BY Application (USD Billion)
  1. 4.4.1 Diagnostics
  2. 4.4.2 Surveillance
  3. 4.4.3 Treatment Monitoring
  4. 4.4.4 Prognosis
5. 4.5 Healthcare, BY End User (USD Billion)
  1. 4.5.1 Hospitals
  2. 4.5.2 Clinics
  3. 4.5.3 Laboratories
  4. 4.5.4 Research Institutions
  5. 4.5.5 Public Health Agencies
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Abbott Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche Diagnostics (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Thermo Fisher Scientific (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Siemens Healthineers (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 BioMérieux (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Cepheid (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hologic (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 QuidelOrtho (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 PerkinElmer (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 US MARKET ANALYSIS BY SPECIMEN TYPE
5. 6.5 US MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 US MARKET ANALYSIS BY APPLICATION
7. 6.7 US MARKET ANALYSIS BY END USER
8. 6.8 CANADA MARKET ANALYSIS BY DISEASE TYPE
9. 6.9 CANADA MARKET ANALYSIS BY SPECIMEN TYPE
10. 6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY
11. 6.11 CANADA MARKET ANALYSIS BY APPLICATION
12. 6.12 CANADA MARKET ANALYSIS BY END USER
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY DISEASE TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY SPECIMEN TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY TECHNOLOGY
17. 6.17 GERMANY MARKET ANALYSIS BY APPLICATION
18. 6.18 GERMANY MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY DISEASE TYPE
20. 6.20 UK MARKET ANALYSIS BY SPECIMEN TYPE
21. 6.21 UK MARKET ANALYSIS BY TECHNOLOGY
22. 6.22 UK MARKET ANALYSIS BY APPLICATION
23. 6.23 UK MARKET ANALYSIS BY END USER
24. 6.24 FRANCE MARKET ANALYSIS BY DISEASE TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY SPECIMEN TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY TECHNOLOGY
27. 6.27 FRANCE MARKET ANALYSIS BY APPLICATION
28. 6.28 FRANCE MARKET ANALYSIS BY END USER
29. 6.29 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY SPECIMEN TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
32. 6.32 RUSSIA MARKET ANALYSIS BY APPLICATION
33. 6.33 RUSSIA MARKET ANALYSIS BY END USER
34. 6.34 ITALY MARKET ANALYSIS BY DISEASE TYPE
35. 6.35 ITALY MARKET ANALYSIS BY SPECIMEN TYPE
36. 6.36 ITALY MARKET ANALYSIS BY TECHNOLOGY
37. 6.37 ITALY MARKET ANALYSIS BY APPLICATION
38. 6.38 ITALY MARKET ANALYSIS BY END USER
39. 6.39 SPAIN MARKET ANALYSIS BY DISEASE TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY SPECIMEN TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY TECHNOLOGY
42. 6.42 SPAIN MARKET ANALYSIS BY APPLICATION
43. 6.43 SPAIN MARKET ANALYSIS BY END USER
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY SPECIMEN TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END USER
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY DISEASE TYPE
51. 6.51 CHINA MARKET ANALYSIS BY SPECIMEN TYPE
52. 6.52 CHINA MARKET ANALYSIS BY TECHNOLOGY
53. 6.53 CHINA MARKET ANALYSIS BY APPLICATION
54. 6.54 CHINA MARKET ANALYSIS BY END USER
55. 6.55 INDIA MARKET ANALYSIS BY DISEASE TYPE
56. 6.56 INDIA MARKET ANALYSIS BY SPECIMEN TYPE
57. 6.57 INDIA MARKET ANALYSIS BY TECHNOLOGY
58. 6.58 INDIA MARKET ANALYSIS BY APPLICATION
59. 6.59 INDIA MARKET ANALYSIS BY END USER
60. 6.60 JAPAN MARKET ANALYSIS BY DISEASE TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY SPECIMEN TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY TECHNOLOGY
63. 6.63 JAPAN MARKET ANALYSIS BY APPLICATION
64. 6.64 JAPAN MARKET ANALYSIS BY END USER
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY SPECIMEN TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END USER
70. 6.70 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY SPECIMEN TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
73. 6.73 MALAYSIA MARKET ANALYSIS BY APPLICATION
74. 6.74 MALAYSIA MARKET ANALYSIS BY END USER
75. 6.75 THAILAND MARKET ANALYSIS BY DISEASE TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY SPECIMEN TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY TECHNOLOGY
78. 6.78 THAILAND MARKET ANALYSIS BY APPLICATION
79. 6.79 THAILAND MARKET ANALYSIS BY END USER
80. 6.80 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY SPECIMEN TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
83. 6.83 INDONESIA MARKET ANALYSIS BY APPLICATION
84. 6.84 INDONESIA MARKET ANALYSIS BY END USER
85. 6.85 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY SPECIMEN TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
88. 6.88 REST OF APAC MARKET ANALYSIS BY APPLICATION
89. 6.89 REST OF APAC MARKET ANALYSIS BY END USER
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY SPECIMEN TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
94. 6.94 BRAZIL MARKET ANALYSIS BY APPLICATION
95. 6.95 BRAZIL MARKET ANALYSIS BY END USER
96. 6.96 MEXICO MARKET ANALYSIS BY DISEASE TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY SPECIMEN TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY TECHNOLOGY
99. 6.99 MEXICO MARKET ANALYSIS BY APPLICATION
100. 6.100 MEXICO MARKET ANALYSIS BY END USER
101. 6.101 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY SPECIMEN TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
104. 6.104 ARGENTINA MARKET ANALYSIS BY APPLICATION
105. 6.105 ARGENTINA MARKET ANALYSIS BY END USER
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY SPECIMEN TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY SPECIMEN TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY SPECIMEN TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER
122. 6.122 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY SPECIMEN TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
125. 6.125 REST OF MEA MARKET ANALYSIS BY APPLICATION
126. 6.126 REST OF MEA MARKET ANALYSIS BY END USER
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY SPECIMEN TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY SPECIMEN TYPE, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY END USER, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.2.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.2.5 BY END USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.3.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.3.5 BY END USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.4.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.4.5 BY END USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.5.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.5.5 BY END USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.6.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.6.5 BY END USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.7.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.7.5 BY END USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.8.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.8.5 BY END USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.9.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.9.5 BY END USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.10.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.10.5 BY END USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.11.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.11.5 BY END USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.12.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.12.5 BY END USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.13.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.13.5 BY END USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.14.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.14.5 BY END USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.15.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.15.5 BY END USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.16.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.16.5 BY END USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.17.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.17.5 BY END USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.18.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.18.5 BY END USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.19.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.19.5 BY END USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.20.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.20.5 BY END USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.21.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.21.5 BY END USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.22.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.22.5 BY END USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.23.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.23.5 BY END USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.24.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.24.5 BY END USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.25.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.25.5 BY END USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.26.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.26.5 BY END USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.27.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.27.5 BY END USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.28.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.28.5 BY END USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.29.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.29.5 BY END USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY SPECIMEN TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
  4. 7.30.4 BY APPLICATION, 2025-2035 (USD Billion)
  5. 7.30.5 BY END USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Viral Disease Diagnosis Market Segmentation

Viral Disease Diagnosis Market By Disease Type (USD Billion, 2025-2035)

HIV
Hepatitis
Influenza
Respiratory Syncytial Virus (RSV)
Cytomegalovirus (CMV)
Epstein-Barr Virus (EBV)
Herpes Simplex Virus (HSV)

Viral Disease Diagnosis Market By Specimen Type (USD Billion, 2025-2035)

Blood
Urine
Saliva
Swabs
Sputum
Stool

Viral Disease Diagnosis Market By Viral Disease Diagnosis Market (USD Billion, 2025-2035)

Nucleic Acid Amplification Tests (NAATs)
Immunoassays
Serology Tests
Molecular Diagnostics
Rapid Diagnostic Tests

Viral Disease Diagnosis Market By Application (USD Billion, 2025-2035)

Diagnostics
Surveillance
Treatment Monitoring
Prognosis

Viral Disease Diagnosis Market By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Laboratories
Research Institutions
Public Health Agencies

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”